Stock listing
Curasight A/s
Selected listing: CURAS · NGM · DKK · SE
Curasight A/s (NGM:CURAS), Health Technology. Latest release Jul 27, 2026: Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive…
- Ticker
- NGM:CURAS
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Medical Specialties
- Exchange
- NGM
- Currency
- DKK
About Curasight A/s
Curasight A/S is a public company traded under the ticker CURAS on the Swedish market. Curasight focuses on developing innovative solutions in the healthcare sector, particularly in the field of targeted cancer diagnostics and treatment.
Latest news from Curasight A/s
Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma)
July 27, 2026
Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million
June 22, 2026
Curasight A/S announces its intention to carry out a directed issue of shares
June 22, 2026
Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT[®] in Aggressive Brain Cancer (Glioblastoma)
June 8, 2026
Curasight: Major Shareholding Notification - share transfer and ownership restructuring – related party transaction
April 26, 2026